Mother Nature’s Genius: Understanding Phytosynthesis Reveals Access to Naturally Occurring but Rare Minor Cannabinoids with Therapeutic Properties

Because botanical medicine is inconsistent by Nature, Cannamimetics™ allows a smoothing and enhancement of the variability in extracts and concentrates made from plants, harvest to harvest, to ensure consumers are afforded the ideal amount and combination of the healing attributes of bioactive cannabinoids, including terpenes, flavonoids, polyphenols and other nutrients from hemp. Consistency results in superior plant remedies.

Similar to the potency differences of cannabinoids in hemp, important terpenes vary plant to plant and year to year, based on genetic, environmental and developmental factors. Cannamimetics can be applied to follow the terpene synthases pathways, similar to cannabinoid synthases, involving encoded enzymes and complex interactions that result in pharmacologically active classes of metabolites that improve human health.

At some point, generational breeding and/or systems utilizing CRISPR genome editing techniques will yield “minor” cannabinoids and important terpenes in greater abundance but it is taking time. The estimated biological maximum of oil is approximately 30-40% by weight in the plant – remember the plant does many things during its life other than make oil and push it into the trichomes. The difficulty of breeding for stable ratios of multiple cannabinoids, e.g., a ratio of CBD:CBG:CBC, 5:1:1 ratio, or CBD:CBN, 1:1 ratio, is why cannamimetics will always have a role in improving the health of many people with highly effective and consistent entourages of phytocompounds.

Genetically engineering organisms to grow in yeast, e. Coli, algae or other host “biofactories” to manufacture cannabinoids in pure forms has been a popular topic in the news lately. This scientific methodology is a pathway that some believe is attractive for the pharma industry and will be a reality at some point in the future. Traditional pharma methods to synthesize both naturally occurring phytocannabinoids and new synthetic analogs or prodrugs will no doubt earn a place in the traditional drug marketplace based on future clinical trials.

At PPM, we believe that the hemp plant’s family tree of cannabinoid offspring and the plant’s inner workings during its life cycle reveal all we need to know to improve human health with plants. With the great advantage of being a hemp-derived botanical product and being able to dial in a consistent profile of naturally occurring plant compounds with therapeutic properties, cannamimetics is essentially the science and application of the phytosynthesis pathways that have evolved in Mother Nature.

Dr. Raphael Mechoulam, considered a living legend for his brilliant and pioneering scientific cannabinoid discoveries, once quipped: “For thousands of years, the only drugs available were drugs from plants.”

PPM’s New CBN and CBG Products

PPM applies cannamimetics science and methodologies to bring its CPG and contract manufacturing company customers whole plant oils and distillates, concentrates, and tailored profiles of cannabinoids, terpenes and other phytochemicals with therapeutic attributes. Consistently.

Just this month, PPM began offering hemp-derived CBN distillate oil at levels of purity greater than 70% and 0.0% THC.

CBG is also now available for sampling and formulation assessment in a whole plant, full spectrum CBD oil or distillate formats at either a 10:1 or 5:1 ratio, CBD:CBG.

PPM scientists are currently working on proprietary techniques to process and purify the acidic versions of cannabinoids recognized to have therapeutic properties. CBC, THC-V, and other cannabinoid-based products are also PPM R&D priorities.

The scientific backgrounds and research CVs of PPM’s R&D team which includes three PhDs in organic chemistry and plant medicine are evidence of PPM’s commitment to advancing the science and providing innovative CBD and minor cannabinoid-based ingredients to leading consumer product supply chains worldwide.

David Symonsbergen
Chief Science Officer

If you have questions, please don’t hesitate to email David at
[email protected]